The FDA Just Approved a New Drug for an Aggressive Form of Prostate Cancer — and It Targets the Disease in a Way No Approved ...

The FDA has approved capivasertib (Truqap) in combination with abiraterone acetate (Zytiga) and prednisone for adults with ...

AstraZeneca Plc AZN received two significant regulatory updates from the U.S. Food and Drug Administration, with its cancer ...

Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...

AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient ...

To address the challenge of finding new combination therapies against castration-sensitive prostate cancer, we introduce Vini, a computational tool that predicts the efficacy of drug combinations at ...

Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...

Androgen deprivation therapy (ADT) has long been the cornerstone of treatment for advanced prostate cancer. Since ...

A comprehensive review of treatment options for patients with metastatic hormone-sensitive prostate cancer. Alicia Morgans, M.D., MPH: Metastatic hormone-sensitive prostate cancer is a particular type ...

Akeega reduced radiographic progression or death risk by 37% in mCSPC patients with HRR gene alterations. Significant reduction in symptomatic progression risk by 50% and a trend towards improved ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Let me introduce ...